The combination of atezolizumab (anti-PD-L1) and bevacizumab (anti-VEGF) produced surprising phase III clinical trial results in unresectable hepatocellular carcinoma (HCC). The gene discussed is VEGFA; the disease is hepatocellular carcinoma.